Search the Newsreel

Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell Carcinoma

Allogene's investigational CAR T candidate, ALLO-316, demonstrated a 31% confirmed response rate in Stage IV renal cell carcinoma patients with high CD70 tumor proportion scores, who had previously failed immune checkpoint blockade and at least one TKI. The Phase 1 TRAVERSE data, published in …

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

Earnings call transcript: Allogene Therapeutics beats EPS expectations in Q1 2026

Allogene schedules May 13 webcast for Q1 results and business update

Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed?

Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Allogene Therapeutics (NASDAQ:ALLO), Sma

Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next

Allogene Therapeutics Stock Surges on Optimistic Trial Results and Price Target Increase

Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast

Cancer CAR T firm Allogene sets March 12 call on 2025 results

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Allogene Therapeutics Stock Surges After Promising Market Developments

Logic Instrument SA: Actionnaires Dirigeants et Profil Société | ALLOG | FR0000044943